Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems, Part II: Long-Term Stability and Clinical Ocular Biopermanence.
Ana Castro-BaladoAndrea Cuartero-MartínezHugo Pena-VerdealGonzalo Hermelo-VidalAnja SchmidtBelén MonteroManuela Hernández-BlancoIrene Zarra-FerroMiguel González-BarciaCristina Mondelo-GarcíaMaría Jesús GiráldezEva Yebra-PimentelFrancisco-Javier Otero-EspinarAnxo Fernandez-FerreiroPublished in: Pharmaceutics (2023)
0.55% cysteamine hydrochloride formulation in HA and packaged in single-dose containers preserved at -20 °C is stable for 120 days protected from light, presenting high potential for its translation into clinical practice when commercial presentations are not available.